Paul Visintainer to Neonatal Abstinence Syndrome
This is a "connection" page, showing publications Paul Visintainer has written about Neonatal Abstinence Syndrome.
Connection Strength
0.848
-
Singh R, Visintainer PF. Adjunctive therapy for neonatal abstinence syndrome: why not personalize it for each infant based on their in-utero exposure? J Perinatol. 2014 Jul; 34(7):575-6.
Score: 0.428
-
King RS, Peacock-Chambers E, Wilson D, Shimer J, Foss S, Visintainer P, Singh R. Impact of maternal medication for opioid use disorder on neurodevelopmental outcomes of infants treated for neonatal opioid withdrawal syndrome. J Neonatal Perinatal Med. 2021; 14(4):463-473.
Score: 0.168
-
Peacock-Chambers E, Leyenaar JK, Foss S, Feinberg E, Wilson D, Friedmann PD, Visintainer P, Singh R. Early Intervention Referral and Enrollment Among Infants with Neonatal Abstinence Syndrome. J Dev Behav Pediatr. 2019 Jul/Aug; 40(6):441-450.
Score: 0.151
-
Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatol. 2013 Dec; 33(12):954-9.
Score: 0.101